Description for experts
The aim of the study is to prove that it is possible to cure at least 75% of all SR patients with a 24-month monotherapy with vinblastine.
Description for laymen
JSON Data
{
"short_title": "ALCL-VBL",
"data_mode": "900",
"data_mode_number": "000002452",
"official_title": "Internationale kooperative prospektive Studie f\u00fcr Kinder und Jugendliche mit Standardrisiko ALK-positiven ALCL zur Wirksamkeit einer Vinblastin Therapie",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "kurativ",
"therapieintervention_value": null,
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2017-002935-40",
"general_contact_email": "Kik-dokuteam-hs65@ukdd.de",
"general_contact_phone": "+49 351-4585035",
"hauptpruefer_dd_name": "Dr. med. Maria Polacik",
"description_laie_de": "Ziel der Studie ist es zu beweisen, dass es m\u00f6glich ist, mindestens 75 % aller SR-Patienten mit einer 24-monatigen Monotherapie mit Vinblastin zu heilen.",
"description_laie_en": null,
"description_expert_de": null,
"description_expert_en": "The aim of the study is to prove that it is possible to cure at least 75% of all SR patients with a 24-month monotherapy with vinblastine.",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "IV",
"main_cat_id": 14,
"sub_cat_id": 65
}
